Arkansas judge Tim Fox, who ruled earlier this year that Janssen Pharmaceuticals and its parent company Johnson & Johnson had concealed risks associated with their antipsychotic Risperdal and levied a fine of $1.2 billion, has denied a J&J request for a new trial. In other news, sources say that J&J is within two weeks of a final settlement with federal prosecutors to resolve allegations of using deceptive tactics to market Risperdal. J&J hopes to avoid a felony charge that would prevent it from marketing Risperdal to government health programs such as medicare.
Risperdal reproached.
Same saga here as Eli Lilly Zyprexa.
Johnson and Johnson is a trusted brand we associate with babies.
Risperdal,Zyprexa,as well as the other atypical antipsychotics, are being prescribed for children, even though this is an unapproved, off-label use. An estimated 2.5 million children are now taking atypical antipsychotics. Over half are being given them for Attention Deficit Hyperactivity Disorder,many of these foster children.
Weight gain, increases in triglyceride levels and associated risks for (life-long) diabetes and cardiovascular disease.
Eli Lilly made $65 BILLION on Zyprexa!
*Tell the truth don’t be afraid*
Daniel Haszard FMI
http://www.zyprexa-victims.com
Report comment